Beijing Institute for Neuroscience, Beijing Center for Neural Regeneration and Repair, Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, Capital Medical University, No.10 Xi tou tiao, You an men, Beijing 100069, P.R. China.
CNS Neurol Disord Drug Targets. 2011 Jun;10(4):509-16. doi: 10.2174/187152711795563921.
Parkinson's disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain Dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however, have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
帕金森病（PD）是一种常见的神经退行性疾病，其特征是中脑多巴胺能（DA）神经元选择性丧失。为了解决这个问题，各种具有分化为 DA 神经元潜力的干细胞被作为 PD 的细胞治疗方法进行研究，包括来自胚胎或成体供体组织的细胞和胚胎干细胞。然而，这些细胞来源在伦理和排斥问题上引起了一些关注。最近成体干细胞的进展进一步证明，来自成体组织的细胞可以在体外扩增和分化为 DA 前体细胞，并且成体干细胞的细胞治疗可以使 PD 模型明显改善。将成体干细胞用于临床应用不仅可以克服使用人胎儿组织或胚胎干细胞所固有的伦理问题，而且还为自体移植开辟了可能性。因此，患者特异性成体干细胞是 PD 治疗的一种有潜力和有前景的候选物。
